Arbutus Biopharma (ABUS) Interest Expenses (2010 - 2026)
Arbutus Biopharma (ABUS) posted Interest Expenses of $23000.0 for Q1 2026, up 27.78% sequentially from $18000.0 in Q4 2025, and down 17.86% YoY from $28000.0 in Q1 2025.
Arbutus Biopharma (ABUS) Interest Expenses (2010 - 2026) Analysis & Trends
Arbutus Biopharma has reported Interest Expenses for 17 years, with the latest figure at $23000.0 in Q1 2026.
- Quarterly Interest Expenses fell 17.86% year-over-year to $23000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23000.0 (down 96.93% YoY) and the FY2025 annual result came in at $181.4 million, up 3.4% from the prior year.
- Interest Expenses grew to $23000.0 in Q1 2026 per ABUS's latest filing, from $18000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $509000.0 in Q4 2024 and troughed at $18000.0 in Q4 2025.
- A 5-year average of $191000.0 and a median of $168000.0 in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses jumped 178.14% in 2024, then sank 96.46% in 2025.
- Over 5 years, Interest Expenses stood at $309000.0 in 2022, then plunged by 40.78% to $183000.0 in 2023, then surged by 178.14% to $509000.0 in 2024, then tumbled by 96.46% to $18000.0 in 2025, then increased by 27.78% to $23000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $23000.0, $18000.0, and $23000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | 60,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60,000.00 |
| Jun 30, 2026 | 60,000.00 |
| Mar 31, 2026 | 23,000.00 |
| Mar 31, 2026 | 23,000.00 |
| Dec 31, 2025 | 18,000.00 |
| Dec 31, 2025 | 18,000.00 |
| Sep 30, 2025 | 23,000.00 |
| Sep 30, 2025 | 23,000.00 |
| Jun 30, 2025 | 28,000.00 |
| Jun 30, 2025 | 28,000.00 |
| Mar 31, 2025 | 28,000.00 |
| Mar 31, 2025 | 28,000.00 |
| Dec 31, 2024 | 509,000.00 |
| Dec 31, 2024 | 509,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 97,000.00 |
| Jun 30, 2024 | 97,000.00 |
| Mar 31, 2024 | 168,000.00 |
| Mar 31, 2024 | 168,000.00 |